Molecular Partners AG, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Nedelcovych from TD Cowen maintained a Buy rating on the stock and has a CHF15.00 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Michael Nedelcovych has given his Buy rating due to a combination of factors including Molecular Partners’ distinctive protein engineering platform, which he believes allows the company to pursue oncology opportunities that many competitors cannot. He views the firm’s RadioDARPin technology as both differentiated and advancing quickly, with the DLL3-targeted candidate MP0712 already demonstrating encouraging dosimetry in small cell lung cancer, setting the stage for value-creating clinical readouts this year.
He also sees Molecular Partners as particularly well positioned in radioligand therapy, a large but still underexploited area, because DARPins can more precisely and efficiently target tumor-associated antigens than traditional small molecules or antibodies. Beyond MP0712, the advancing mesothelin-focused MP0726 and a broader pipeline of additional RadioDARPins and Switch DARPins support his view that the company’s platform, and its ability to rapidly generate proof-of-concept through imaging and dosimetry, remains significantly undervalued by the market.